Literature DB >> 9416725

Emulsion formulation reduces propofol's dose requirements and enhances safety.

S Dutta1, W F Ebling.   

Abstract

BACKGROUND: Propofol, a highly lipophilic anesthetic, is formulated in a lipid emulsion for intravenous use. Propofol has brisk onset and offset of effect after rapid administration and retains rapid offset characteristics after long-term administration. The authors tried to determine whether the emulsion vehicle is requisite for propofol's evanescent effect-time profile.
METHODS: The time course of sedation and electroencephalographic (EEG) effect after propofol administration was measured in three studies in rats instrumented. In study 1, propofol was infused in either emulsion or lipid-free vehicle (n = 12), in a repeated measures cross-over design. In study 2, propofol in lipid-free vehicle was infused with or without simultaneous infusion of drug-free lipid emulsion (n = 6) in a repeated measures cross-over design. In study 3, propofol was infused in either emulsion (n = 5) or lipid-free vehicle (n = 5) to EEG burst suppression.
RESULTS: In study 1, relative to the emulsion formulation, propofol administered at equivalent doses in lipid-free vehicle resulted in a longer time to effect onset (1.4 +/- 0.2 vs. 0.5 +/- 0.1 min, EEG) and a trend for delayed anesthetic recovery (26.8 +/- 9.4 vs. 17 +/- 3.5 min, EEG; 26.1 +/- 8.8 vs. 16.8 +/- 3.3 min, sleep). In study 2, coadministration of drug-free emulsion with propofol did not alter the time course of effect. In study 3, more than twice the dose of propofol was required to achieve EEG burst suppression with the lipid-free formulation. Two animals died after administration of propofol to EEG burst suppression with the lipid-free formulation; no deaths occurred in the emulsion group.
CONCLUSION: The incorporation of propofol in emulsion reduces dose requirements and produces rapid onset and recovery of anesthetic effect.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9416725     DOI: 10.1097/00000542-199712000-00019

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  6 in total

1.  Pharmacokinetics and pharmacodynamics of a new reformulated microemulsion and the long-chain triglyceride emulsion of propofol in beagle dogs.

Authors:  S-H Lee; J-L Ghim; M-H Song; H-G Choi; B-M Choi; H-M Lee; E-K Lee; Y-J Roh; G-J Noh
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

2.  A novel, lipid-free nanodispersion formulation of propofol and its characterization.

Authors:  Hongming Chen; Zhong Zhang; Orn Almarsson; Jean-Francois Marier; Dina Berkovitz; Colin R Gardner
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

3.  Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection.

Authors:  C A Knibbe; H J Voortman; L P Aarts; P F Kuks; R Lange; H J Langemeijer; M Danhof
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

4.  Pilot study in humans on the pharmacokinetics and safety of propofol 6% SAZN.

Authors:  C A Knibbe; V S Koster; L P Aarts; H J Langemeijer; M Danhof
Journal:  Pharm World Sci       Date:  1999-10

5.  In vivo and in vitro pharmacological studies of methoxycarbonyl-carboetomidate.

Authors:  Ervin Pejo; Joseph F Cotten; Elizabeth W Kelly; Ri Le Ge; Gregory D Cuny; Joydev K Laha; Jifeng Liu; Xiang Jie Lin; Douglas E Raines
Journal:  Anesth Analg       Date:  2011-09-29       Impact factor: 5.108

6.  Gastrointestinal delivery of propofol from fospropofol: its bioavailability and activity in rodents and human volunteers.

Authors:  Krystyna M Wozniak; James J Vornov; Bipin M Mistry; Ying Wu; Rana Rais; Barbara S Slusher
Journal:  J Transl Med       Date:  2015-05-29       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.